RAI Doc 2, 2017.01.16 Goldman Valuation Report by unknown
Penn State Law 
Penn State Law eLibrary 
M&A Valuation Documents 
1-16-2017 
RAI Doc 2, 2017.01.16 Goldman Valuation Report 
Follow this and additional works at: https://elibrary.law.psu.edu/valuation 
Recommended Citation 
"RAI Doc 2, 2017.01.16 Goldman Valuation Report" (2017). M&A Valuation Documents. 53. 
https://elibrary.law.psu.edu/valuation/53 
This RAI is brought to you for free and open access by Penn State Law eLibrary. It has been accepted for inclusion 
in M&A Valuation Documents by an authorized administrator of Penn State Law eLibrary. For more information, 








Goldman Sachs  
Table of Contents  
INVESTMENT BANKING DIVISION  
I. Review of Braves Proposal and Market Contex t  
II. Illustrative Financial Analyses of Royals  
III. Review of Stand-alone Braves and Illustrat ive Combination Analysis  




Goldman Sachs  
INVESTMENT BANKING DIVISION  
I. Review of Braves Proposal and Market Contex t  
 
CONFIDENTIAL  
Goldman Sachs  
Comparison of Braves Ini tial vs . Current Offer  
INVESTMENT BANKING DIVISION  







CONFIDENTIAL No te: 10-Jan offer assumes $29.44 cash per share and 0.2630x ADS exchange ratio based on Braves AD S share price of $115.21  per Bloomberg.  
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Median 1 Day  Premia on Cash / Stoc k Transactions  
Proposed Transaction: 28.0  % 1 32.5% 34.4% 33.4%  
31.1% 31.6%  
Precedent Transactions Median: 26.0 % 26 .0% 27.3%  
22.2%  
16.9% 16.3% 17.9%  
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11.7%  
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Comparison of Braves Forecast vs. Wall Street Research Estimates  
INVESTMENT BANKING DIVISION  
(£ in millions, except per share data)  
Braves Forecast IBE S Variance  
‘16- ‘18 ‘16- ‘18 ‘16- ‘18  
2016 2017  2018 CAGR 2016 2017 2018 CAG R 2016 2017 2018 CAGR  
Net Sales £14,805 £16 ,316 £16,969 7 .1 % £14,844 £16 ,333 £16,949 6 .9% £(38) £(17) £20 0.2%  
% Growth 13.0 % 10.2 % 4.0 % 13.3 % 10.0 % 3.8 % (0.3)% 0.2% 0.2%  
EBITDA £5,901 £6,405 £6,769 7.1 % £5,859 £6,566 £6,905 8.6% £42 £(161) £(136) (1.5)%  
% Margin 39.9 % 39.3 % 39.9 % 39.5 % 40.2 % 40 .7 % 0.4% (0.9)% (0.8)%  
Net Income £4,711 £5,240 £5,652 9.5 % £4,623 £5,280 £5,656 10.6% £88 £(40) £(4) (1.1)%  
% Growth 21.3 % 11.2 % 7.9 % 19.1 % 14.2 % 7.1 % 2.3% (3.0)% 0.7%  
EPS £2.51 £2.80 £3 .02 9.5 % £2.46 £2.81 £3 .05 11.3% £0.05 £(0.02) £(0.04) (1.8)%  
% Growth 20.6 % 11.2 % 7.9 % 18.2 % 14.2 % 8.5 % 2.4% (3.0)% (0.6)%  
DPS £1.63 £1.82 £1.96 9.5 % £1.64 £1.81 £2.00 10.4%  £(0.01) £0.01 £(0.04) (0.9)%  
% Payout 65.0 % 65.0 % 65.0 % 66.6 % 64.3 % 65.5 % (1.6)% 0.7% (0.5)%  
Source: Braves Forecast, IBES as of 13-Jan-2017  
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CONFIDENTIAL Go ldman Sachs Royals Illustrative Weigh ted Average Cost of Capital  INVEST MENT BAN KING DIVISION Illus trative WACC Calcu lation A s of 13-Jan-17 Assumptions Risk Free Rate (RF) 1 2.7% Mar ket Risk Premium (Rp) 2 6.9% Tax Rate (t) 38.6% Pre-Tax Cost of Deb t 3 3.5% Target Capital Structure Debt / T otal Capitalization 4 15.2% Equity  / Target Capital izat ion 84.8% Weighted Average Cos t of Cap ital After-Tax Cos t of Debt 2.1% Assumed Equity  Beta (Be)5 0.55 Cost of Equity  6.5% WA CC 5.9 % Equity  Beta Debt / To tal Capitalization 5.0 % 15 .0% 25.0% 0.50 6.0% 5.6% 5.2% 0.55 6 .3% 5.9% 5.4% 0.60 6 .6% 6.2% 5.7% Tobacco Landscape Metrics Equity  Beta Asset Beta Current Debt /  Total Capital izat ion Net Debt / Total Capitalization T obacco Landscape Axioma Historical Axioma Predicted Axioma Historical  
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